









Markets
/
Stocks
/
nasdaq-gpcr
/

Structure Therapeutics Inc

GPCR

32.210USD

-1.800-5.29%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

5.56BMarket Cap

LossP/E TTM



Structure Therapeutics Inc

32.210

-1.800-5.29%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Structure Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Structure Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

204 / 501

Overall Ranking

359 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Buy

Current Rating

75.846

Target Price

+131.52%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Structure Therapeutics Inc Highlights

StrengthsRisks

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -27.45, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 57.81M shares, decreasing 19.53% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 111.90K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Structure Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 7.10, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -27.45, which is -43.46% below the recent high of -15.52 and -16.45% above the recent low of -31.97.

Score

Industry at a Glance

Previous score

7.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 204/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.80, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Structure Therapeutics Inc is 65.00, with a high of 120.00 and a low of 50.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Buy

Current Rating

75.846

Target Price

+123.01%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Structure Therapeutics Inc

GPCR

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 7.15, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 31.49 and the support level at 25.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.65

Change

0.5

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.672

Buy

RSI(14)

63.790

Neutral

STOCH(KDJ)(9,3,3)

81.879

Neutral

ATR(14)

1.684

High Vlolatility

CCI(14)

88.621

Neutral

Williams %R

25.702

Buy

TRIX(12,20)

0.812

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

32.904

Sell

MA10

30.464

Buy

MA20

29.560

Buy

MA50

25.768

Buy

MA100

22.454

Buy

MA200

22.708

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 100.37%, representing a quarter-over-quarter decrease of 3.25%. The largest institutional shareholder is The Vanguard, holding a total of 582.45K shares, representing 1.01% of shares outstanding, with 0.54% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Wellington Management Company, LLP

6.88M

-11.75%

Deep Track Capital LP

5.13M

+25.22%

Fidelity Management & Research Company LLC

4.73M

-18.47%

Janus Henderson Investors

4.57M

+5.00%

Baker Bros. Advisors LP

2.51M

+593.86%

BVF Partners L.P.

1.66M

-6.17%

Capital International Investors

1.62M

-0.01%

RA Capital Management, LP

1.52M

Citadel Advisors LLC

1.33M

+33.87%

Casdin Capital, LLC

1.23M

+75.00%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.